Antibody-Drug Conjugates (ADCs) for Breast Cancer Therapeutic Landscape: Concept and Mechanisms of Action

The concept of a “magic bullet” in oncology—first envisioned by Paul Ehrlich—has evolved into one of the most dynamic areas in precision cancer therapeutics: antibody–drug conjugates (ADCs). These biopharmaceuticals combine the selectivity of monoclonal antibodies with the potency of cytotoxic agents through specialized linkers, achieving targeted delivery of chemotherapeutic compounds to malignant cells while minimizing systemic toxicity. This narrative review explores the molecular foundations, pharmacologic mechanisms, and clinical evolution of ADCs, emphasizing their transformative impact on breast cancer management. ADCs are structured around three essential components: an antibody that binds a tumor-specific antigen, a linker that ensures controlled payload release, and a cytotoxic drug that induces apoptosis once internalized. The interaction of the ADC–antigen complex leads to endocytosis, lysosomal degradation, and payload liberation. Depending on the properties of the linker and the permeability of the cytotoxic payload, the cytotoxic effect can extend to neighboring cells—a phenomenon termed the bystander effect. Advances in linker chemistry, such as the use of acid-labile, enzyme-labile, or disulfide-cleavable bonds, together with the humanization of antibody backbones, have significantly improved pharmacokinetics, stability, and safety. The evolution of ADC generations illustrates progressive refinements in bioengineering and therapeutic efficacy. First-generation ADCs, such as Gemtuzumab ozogamicin, demonstrated the proof of concept but suffered from high immunogenicity, poor selectivity, and heterogeneous drug–antibody ratios. Second-generation ADCs introduced stable linkers and humanized antibodies, exemplified by Ado-trastuzumab emtansine (T-DM1), which targets the HER2 receptor in breast cancer. Clinical trials such as EMILIA and HER2CLIMB-02 confirmed improved survival outcomes and reduced toxicity compared with conventional chemotherapy. Third-generation ADCs, including Trastuzumab deruxtecan and Sacituzumab govitecan, incorporate site-specific conjugation, higher drug-to-antibody ratios, and potent payloads capable of inducing bystander killing even in tumors with low antigen expression. Landmark studies such as DESTINY-Breast03, DESTINY-Breast04, DESTINY-Breast06, ASCENT, and TROPiCS-02 have positioned these agents as pivotal therapies across HER2-positive, HER2-low, and triple-negative breast cancer subtypes. Despite these advances, resistance mechanisms remain a significant challenge. These include antigen downregulation, overexpression of efflux pumps, impaired intracellular trafficking, and reduced payload activation. Nevertheless, the modular architecture of ADCs allows iterative optimization of their antibody, linker, and payload components to overcome these barriers. Future developments are exploring bispecific ADCs that target multiple antigens, radiolabeled or immune-activating conjugates, and masked ADCs engineered for selective activation within tumor microenvironments, all of which aim to further refine selectivity, potency, and therapeutic benefit. In conclusion, ADCs exemplify the convergence of molecular biology, immunology, and medicinal chemistry in the pursuit of precision oncology. Their progressive evolution from concept to clinic not only validates Ehrlich’s century-old vision but also heralds a new therapeutic era in which cancer treatment achieves unprecedented specificity, efficacy, and improvement in patient outcomes.